Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intuniv

- PMLiVE

Shire claims US okay for HAE blockbuster-in-waiting

FDA approves Takhzyro as a preventative measure for HAE attacks

- PMLiVE

UK says firms should stockpile drugs in case of no-deal Brexit

Government also confirms the MHRA will handle UK marketing applications for new medicines

- PMLiVE

Confidence in UK’s post-Brexit healthcare sector on the wane

Only 37% of healthcare workers agree that the UK would be an attractive destination after EU departure

- PMLiVE

Human Cell Atlas gets new UK funding

The project will allow researchers to define characteristics of single cell types

- PMLiVE

Immunology keeps Shire figures solid as Takeda takeover nears

Shire’s sales increased by 6% to $3.81bn

- PMLiVE

May’s Brexit plan cautiously welcomed by biopharma sector

The white paper says the UK should adhere to EMA regulations post-Brexit

- PMLiVE

Daily Brief: Novartis exits anti-infectives drive, Hancock takes over from Hunt and Trump attacks ‘soft Brexit’ plan

The latest from pharma, biotech and healthcare

- PMLiVE

ABPI blames doctor payment disclosure dip on GDPR

Figures drop to 49% from almost 65% last year

- PMLiVE

Daily Brief: Dementia Fund hits $350m mark, hard Brexit could cost £100bn in trade and troublesome results for Pfizer’s Ibrance

The latest news from across pharma, biotech and healthcare

- PMLiVE

Irish survey lists pharma firms’ top five Brexit concerns

Talent access restrictions topped the list

- PMLiVE

NHS could save £7bn with greater diagnostics use

Report suggests IVD tests could be key to big savings

- PMLiVE

May earmarks £20bn for the NHS – but experts say it’s not enough

But claims of a “Brexit dividend” are rubbished

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links